title: Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
abstract: Since in most tumors multiple signaling pathways are involved, many of the inhibitors in clinical development are designed to affect a wide range of targeted kinases. The most important tyrosine kinase families in the development of tyrosine kinase inhibitors are the ABL, SCR, platelet derived growth factor, vascular endothelial growth factor receptor and epidermal growth factor receptor families. Both multi-kinase inhibitors and single-kinase inhibitors have advantages and disadvantages, which are related to potential resistance mechanisms, pharmacokinetics, selectivity and tumor environment. In different malignancies various tyrosine kinases are mutated or overexpressed and several resistance mechanisms exist. Pharmacokinetics is influenced by interindividual differences and differs for two single targeted inhibitors or between patients treated by the same tyrosine kinase inhibitor. Different tyrosine kinase inhibitors have various mechanisms to achieve selectivity, while differences in gene expression exist between tumor and stromal cells. Considering these aspects, one type of inhibitor can generally not be preferred above the other, but will depend on the specific genetic constitution of the patient and the tumor, allowing personalized therapy. The most effective way of cancer treatment by using tyrosine kinase inhibitors is to consider each patient/tumor individually and to determine the strategy that specifically targets the consequences of altered (epi)genetics of the tumor. This strategy might result in treatment by a single multi kinase inhibitor for one patient, but in treatment by a couple of single kinase inhibitors for other patients.
authors: Fleur Broekman, Elisa Giovannetti, Godefridus J Peters, Department of Medical Oncology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands.
authors: Fleur
authors: F
authors: Broekman
authors: Elisa
authors: E
authors: Giovannetti
authors: Godefridus J
authors: GJ
authors: Peters
references: Cancer Lett. 2007 Oct 28;256(2):137-65
references: 17629396
references: Cell. 2000 Oct 13;103(2):211-25
references: 11057895
references: Curr Pharm Des. 2004;10(27):3431-42
references: 15544526
references: Biochem Pharmacol. 2010 Sep 1;80(5):550-60
references: 20371362
references: Br J Cancer. 2004 Jun 14;90(12):2250-5
references: 15150574
references: J Clin Oncol. 2002 Mar 15;20(6):1657-67
references: 11896117
references: N Engl J Med. 2009 Sep 3;361(10):947-57
references: 19692680
references: Blood. 2004 Dec 1;104(12):3754-7
references: 15304388
references: Pharmacogenomics. 2011 Feb;12(2):159-70
references: 21332310
references: Science. 2002 Dec 6;298(5600):1912-34
references: 12471243
references: Br J Cancer. 2006 Jun 19;94(12):1765-9
references: 16721371
references: Science. 2001 Aug 3;293(5531):876-80
references: 11423618
references: Cancer Res. 1999 Sep 15;59(18):4681-7
references: 10493525
references: Br J Cancer. 2008 Mar 11;98(5):857-62
references: 18253130
references: Eur J Cancer. 2002 Sep;38 Suppl 5:S70-6
references: 12528776
references: Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44
references: 16467097
references: Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S4-11
references: 15552621
references: Leuk Lymphoma. 2010 Apr;51(4):583-91
references: 20302388
references: J Biol Chem. 2000 Apr 28;275(17):12661-6
references: 10777558
references: Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14907-12
references: 16997913
references: Cancer Res. 2003 Sep 15;63(18):6063-8
references: 14522936
references: Cancer Immunol Immunother. 2008 Jan;57(1):1-17
references: 17661033
references: Science. 2004 Jul 16;305(5682):399-401
references: 15256671
references: Cancer Cell. 2002 Mar;1(2):117-23
references: 12086869
references: Mol Cancer Ther. 2006 May;5(5):1280-9
references: 16731761
references: Blood. 2003 Jan 15;101(2):690-8
references: 12509383
references: Cancer Cell. 2005 Feb;7(2):129-41
references: 15710326
references: J Med Chem. 2007 Feb 8;50(3):409-24
references: 17266192
references: Oncologist. 2007 Jan;12(1):107-13
references: 17227905
references: J Clin Oncol. 2001 Sep 15;19(18 Suppl):32S-40S
references: 11560969
references: Bioinformatics. 2007 Aug 1;23(15):1919-26
references: 17537753
references: Clin Cancer Res. 2007 May 15;13(10):2890-6
references: 17504988
references: Int J Surg Pathol. 2004 Jan;12(1):1-9
references: 14765266
references: Clin Cancer Res. 2003 Feb;9(2):625-32
references: 12576428
references: Clin Cancer Res. 2006 Oct 1;12(19):5764-9
references: 17020982
references: Curr Opin Struct Biol. 2002 Dec;12(6):735-41
references: 12504677
references: Clin Cancer Res. 2006 Apr 15;12(8):2538-44
references: 16638863
references: J Clin Oncol. 2002 Mar 15;20(6):1692-703
references: 11896121
references: Nat Rev Cancer. 2005 Mar;5(3):172-83
references: 15719031
references: Cancer Res. 2005 Mar 1;65(5):1778-82
references: 15753374
references: Blood. 2005 May 15;105(10):3995-4003
references: 15657179
references: Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71
references: 16609030
references: J Clin Oncol. 2009 Sep 10;27(26):4406-12
references: 19667267
references: J Med Chem. 1996 Jun 7;39(12):2285-92
references: 8691423
references: Drugs. 2000 Mar;59(3):435-76
references: 10776829
references: Blood. 2003 Oct 15;102(8):2763-7
references: 12843001
references: Oncologist. 2007 Apr;12(4):443-50
references: 17470687
references: Clin Cancer Res. 2007 Jun 15;13(12):3731-7
references: 17575239
references: Drug Saf. 2009;32(12):1123-34
references: 19916579
references: Gastroenterology. 2005 Feb;128(2):270-9
references: 15685537
references: J Clin Oncol. 2005 Nov 1;23(31):8081-92
references: 16204011
references: Lancet Oncol. 2010 Feb;11(2):121-8
references: 20022809
references: IDrugs. 2008 Jan;11(1):46-56
references: 18175263
references: Biochem Soc Trans. 2007 Aug;35(Pt 4):698-700
references: 17635126
references: Clin Cancer Res. 2008 Nov 1;14(21):7102-9
references: 18981009
references: Mol Cancer Ther. 2010 Mar;9(3):581-93
references: 20159991
references: J Med Chem. 2006 Jun 1;49(11):3092-100
references: 16722629
references: Lung Cancer. 2007 Apr;56(1):135-7
references: 17157952
references: Br J Cancer. 1995 Sep;72(3):708-14
references: 7669585
references: Endocr Relat Cancer. 2004 Dec;11(4):689-708
references: 15613446
references: Cancer Res. 2005 Apr 1;65(7):2577-82
references: 15805252
references: Blood. 2005 Jul 15;106(2):721-4
references: 15790786
references: J Clin Oncol. 2009 Sep 10;27(26):4274-80
references: 19652055
references: Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1992-7
references: 15677719
references: Hematology Am Soc Hematol Educ Program. 2005;:183-7
references: 16304378
references: Science. 2004 Jun 4;304(5676):1497-500
references: 15118125
references: Histopathology. 2006 Jan;48(1):83-96
references: 16359540
references: Biochem J. 2000 Oct 1;351(Pt 1):95-105
references: 10998351
references: Nat Rev Mol Cell Biol. 2004 Jun;5(6):464-71
references: 15173825
references: Ann Oncol. 2006 Jul;17(7):1120-7
references: 16600976
references: Blood. 2002 Sep 1;100(5):1532-42
references: 12176867
references: Eur J Cancer. 2010 Jul;46(11):2010-9
references: 20621734
references: Nature. 2002 Dec 19-26;420(6917):860-7
references: 12490959
references: N Engl J Med. 2006 Dec 28;355(26):2733-43
references: 17192538
references: Drug Resist Updat. 2005 Jun;8(3):119-29
references: 15869901
references: Clin Cancer Res. 2010 Jun 1;16(11):3078-87
references: 20395213
references: Cell Cycle. 2004 Dec;3(12):1502-5
references: 15611623
references: Ann Surg Oncol. 2007 Feb;14(2):942-53
references: 17103252
references: Mol Cancer Ther. 2009 Jul;8(7):1924-33
references: 19567819
references: Cancer Res. 2005 Mar 1;65(5):1770-7
references: 15753373
references: Science. 2007 May 18;316(5827):1039-43
references: 17463250
references: Clin Cancer Res. 2006 Dec 15;12(24):7232-41
references: 17189394
references: N Engl J Med. 2004 May 20;350(21):2129-39
references: 15118073
references: Blood. 2004 Oct 15;104(8):2532-9
references: 15256422
references: Blood. 2004 Dec 1;104(12):3739-45
references: 15315971
references: Ann Pharmacother. 2006 Feb;40(2):261-9
references: 16418322
references: Oncogene. 2000 Nov 20;19(49):5548-57
references: 11114734
references: Cancer Res. 2004 Oct 1;64(19):7099-109
references: 15466206
references: Pharmacol Ther. 2002 Feb-Mar;93(2-3):79-98
references: 12191602
references: Cancer Biol Ther. 2005 Jul;4(7):747-52
references: 15970668
references: Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):114-20
references: 20728698
references: Clin Biochem. 2004 Jul;37(7):618-35
references: 15234243
references: N Engl J Med. 2006 Jun 15;354(24):2542-51
references: 16775235
references: Cancer Treat Rev. 2009 Dec;35(8):692-706
references: 19733976
references: Clin Cancer Res. 2004 Feb 15;10(4):1241-9
references: 14977821
references: Eur J Cancer. 2007 Mar;43(4):676-82
references: 17239582
references: Cancer Res. 2000 Dec 15;60(24):7002-7
references: 11156403